Dr Elena Garralda is a Medical Oncologist, Principal Investigator and Researcher. Currently the Director of Early Drug Development and Co-director of the Clinical Research Program at VHIO. Dedicated to translational research, she coordinates the phase I program and the clinical research program, where complex clinical trials with drugs in early development (phase I and early phase II) focus on targeted agents and immunotherapies, with special emphasis in cell signaling, cancer stem cells, immuno-oncology and first-in-human studies of targeted therapies, rational combinations, and biomarker-driven trials. Dr Garralda is chair of ESMO’s Early Drug Development Track, member of ENA’s Scientific Committee, faculty of the “Methods in Clinical Cancer Research” annual workshop, chair of EORTC’s RECIST Task Force and the Clinical Trials leader for the Cancer Core Europe Consortium among other working groups and associations. She has authored over 100 articles published in peer-reviewed journals including Journal of Clinical Oncology, Nature Medicine and New England Journal of Medicine, has presented more than 150 abstracts and posters in international congresses as AACR, ESMO, ASCO, TAT or ENA, and serves as reviewer for JAMA Oncology, Annals of Oncology, Cancer Treatment Reviews, British Journal of Cancer, Clinical Cancer Research, Lancet Oncology, Nature Reviews or ESMO Open among others.